Lumos Pharma, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Lumos Pharma has completed its merger with DPV Merger Sub, resulting in the company becoming a wholly-owned subsidiary of DPV Parent, Inc. and ceasing to be listed on the Nasdaq.
Lumos Pharma received a delisting notice from Nasdaq due to insufficient stockholders' equity, while also announcing positive Phase 2 clinical trial results for its drug LUM-201.